Laurus Labs Gains Momentum as CDMO Segment Drives Growth

Laurus Labs is undergoing a significant structural transformation, shifting from a traditional API player to a high-value Contract Development and Manufacturing Organisation (CDMO) powerhouse. With shares surging 30% in just two months, the company is leveraging improved product mixes and operating leverage to fuel its next phase of expansion.

Strategic Shift Toward High-Value CDMO Services

A key driver behind the bullish sentiment is Laurus Labs' successful pivot toward higher-margin segments. Six years ago, the CDMO segment contributed only 13% to total revenue; today, that figure has climbed to over 30%. The company has set an ambitious target to have CDMO accounting for 50% of its total revenue by FY30.

This transition is also characterized by a reduced reliance on legacy products. The company's contribution from antiretroviral (ARV) therapies has dropped from 67% to approximately 41%, allowing more room for high-growth areas. In FY26, the CDMO segment witnessed a robust 36% year-on-year growth, reaching ₹2,080 crore, supported by late-stage pipeline progress and increased outsourcing from global pharmaceutical giants.

Robust Margin Expansion and Diversification

Financial performance has been bolstered by significant improvements in profitability. The company’s EBITDA margin expanded by 670 basis points year-on-year to reach 26.8%. This expansion is primarily attributed to higher operating leverage, though management remains cautious of potential volatility in raw material prices.

Beyond its core pharmaceutical business, Laurus Labs is aggressively diversifying into non-pharma sectors, including crop science and animal health. While these segments currently stand at a base of approximately ₹150 crore, Motilal Oswal Financial Services (MOFSL) expects them to scale beyond ₹1,000 crore in the coming years.

Massive ₹3,000-Crore Capex Plan for Capacity Expansion

To sustain this growth trajectory, Laurus Labs has announced a capital expenditure plan of ₹3,000 crore over the next two years. Notably, over 90% of this investment is earmarked for expanding mid and large-scale manufacturing capacities.

Key upcoming projects include:

  • Greenfield Unit 7 Facility: Featuring over 2,000 cubic meters of reactor capacity.
  • Second Commercial Block: Slated for validation by the September 2026 quarter.
  • Specialized Investments: Focused on fermentation, peptides, advanced therapies, and dedicated formulation facilities for animal health.

Analyst Outlook and Earnings Estimates

Brokerages remain optimistic about the company's long-term prospects. Citing strong CDMO traction and steady growth across non-ARV segments, MOFSL has maintained a 'BUY' rating. Analysts have proactively raised earnings estimates for the coming years, projecting an 8% increase for FY27 and a 6% increase for FY28. With the CDMO segment expected to maintain a 22% annual growth rate through FY28, Laurus Labs is well-positioned to capitalize on the global trend of pharmaceutical outsourcing.

Key Takeaways

  • CDMO Transformation: The CDMO segment is expected to grow from its current 30% revenue share to 50% by FY30.
  • Aggressive Expansion: A ₹3,000-crore capex plan is underway, focusing on large-scale manufacturing and advanced therapies.
  • Improved Profitability: EBITDA margins have surged to 26.8%, driven by higher operating leverage and a better product mix.